Brainsway receives expanded FDA labeling to treat late life depression

BrainsWay announced that the US Food and Drug Administration has granted an expanded indication for the Company’s Deep Transcranial Magnetic Stimulation system allowing for the treatment of patients with major depressive disorder ages 22 to 86, changing the previous upper age limit of 68. This represents the Company’s 10th FDA clearance and makes BrainsWay Deep TMS the first and only form of TMS indicated for the treatment of patients over the age of 68 suffering from MDD, including those with comorbid anxiety symptoms.